The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05836857
Collaborator
(none)
100
1
28
3.6

Study Details

Study Description

Brief Summary

To collect information about how patients in the pain management clinic use cannabis/CBD, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on cannabis/CBD for pain management

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cannabis (Marijuana)
  • Behavioral: Cannabidiol (CBD)

Detailed Description

Objectives

Primary Objective:

The primary objective of this study is to investigate the prevalence of current and prior cannabis and/or CBD use in cancer patients who present to the pain management clinic at MDACC.

Secondary Objectives:

The secondary objective is to investigate the reason for cannabis/CBD use (e.g. pain, neuropsychiatric symptoms, recreational or other use), degree of symptom improvement with use, frequency of use, methods of use (e.g. inhaled vs. ingested), sources of information on cannabis/CBD, and patient interest in learning more from their physicians about cannabis/CBD for cancer pain.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
Actual Study Start Date :
Jan 30, 2023
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
May 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Cannabis (Marijuana) and Cannabidiol (CBD)

This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens.

Behavioral: Cannabis (Marijuana)
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.

Behavioral: Cannabidiol (CBD)
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education

Outcome Measures

Primary Outcome Measures

  1. Cannabis (Marijuana) and CBD (Cannabidiol for Cancer Pain Survey [through study completion; an average of 1 year.]

    Score scale ranges from 1-5, Extremely interested(1),Not Interested (5)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 years or older

  2. Cancer patients who present to the MD Anderson Pain Medicine Clinic as a new patient or consult

  3. Willing to give informed consent

  4. Willing to complete the survey

Exclusion Criteria:
  1. Refusal of informed consent

  2. Refusal to complete the survey

  3. Patients who previously completed the survey

  4. Patients who opt-out or change their mind after agreeing to participate

  5. Already an established patient at MDACC Pain Medicine Clinic

  6. Patients scheduled to see Dr Abdi (PI).

Contacts and Locations

Locations

Site City State Country Postal Code
1 M D Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Salahadin Abdi, MD,PHD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT05836857
Other Study ID Numbers:
  • 2022-0049
  • NCI-2023-03440
First Posted:
May 1, 2023
Last Update Posted:
May 1, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 1, 2023